Niosome-Based Delivery Strategies: A Practical Guide for Stable, Cost-Effective Drug Delivery
At Creative Biolabs, we turn niosome-based delivery strategies into practical, scalable solutions for real products. Niosomes offer stable, cost-effective vesicles that protect actives, control release, and improve skin or oral uptake. With smart choices in surfactant, cholesterol ratio, and process, teams can tune size, PDI, and entrapment efficiency for performance. This guide shows how to design, optimize, and scale niosomes—from lab concept to reliable manufacturing.
Introduction: What Are Niosomes?
Niosomes are tiny, bubble-like carriers made from non-ionic surfactants plus cholesterol (Figure 1). Think of them as microscopic packets with a watery center and a fatty shell. Because of this bilayer design, they can hold water-loving drugs in the center and oil-loving drugs in the shell, which helps with difficult-to-dissolve ingredients and protects sensitive actives from breaking down too soon. In simple terms, niosomes help your drug stay stable, travel safely, and release at the right pace to the right place.
How they form and behave depends on a few dial-in choices during formulation: the type of surfactant (e.g., Span/Tween families), the cholesterol ratio (which stiffens the membrane and limits leakage), and the liquid conditions used during preparation (such as pH and temperature). Two helpful ideas guide these choices: the hydrophilic-lipophilic balance (HLB) of the surfactant and the critical packing parameter (CPP). Together, they influence vesicle size, membrane tightness, and loading performance. With the right settings, developers typically target nanoscale sizes with a low polydispersity index for consistent behavior. Because they are biocompatible and versatile, niosomes show a strong fit for topical/transdermal, oral, and even targeted delivery projects.
In short, when teams need stability, controlled release, and cost-effective materials, niosomes are a practical first pick.
Fig.1 The niosome structure.1
How Niosomes Work in Targeted Delivery
How they form and behave depends on a few dial-in choices during formulation: the type of surfactant (e.g., Span/Tween families), the cholesterol ratio (which stiffens the membrane and limits leakage), and the liquid conditions used during preparation (such as pH and temperature). Two helpful ideas guide these choices: the hydrophilic-lipophilic balance (HLB) of the surfactant and the critical packing parameter (CPP). Together, they influence vesicle size, membrane tightness, and loading performance. With the right settings, developers typically target nanoscale sizes with a low polydispersity index for consistent behavior. Because they are biocompatible and versatile, niosomes show a strong fit for topical/transdermal, oral, and even targeted delivery projects.
Niosomes encapsulate the drug, shield it from degradation, and release it in a controlled way. By adjusting bilayer rigidity and surface chemistry, you can influence cellular uptake and biodistribution.
Furthermore, ligand modification (e.g., antibodies, peptides, sugars) enables active targeting. With this, niosomes can accumulate at disease sites, reduce off-target exposure, and improve therapeutic index. Because the platform accepts several payload types, including small molecules, peptides, and some biologics, it is well-suited to oncology, anti-infective, and anti-inflammatory programs.
Tip
Start with passive targeting via size/zeta optimization. Then layer in ligand targeting once you have robust baseline data.
Niosomes vs. Liposomes and Other Nanocarriers
Ligands
Niosomes and liposomes both deliver drugs in vesicles, but they differ in materials and typical behavior (Table 1). When cost, surfactant robustness, and shelf-life are priorities, or developers need stable dermal systems or gel incorporation, niosomes may
- When niosomes are the better option:
Choose niosomes when priorities include low production cost, strong surfactant stability, and extended shelf-life, or when formulating durable dermal systems and gel-based products.
- When liposomes may be more suitable:
Opt for liposomes when you need biomimetic phospholipid structures, established parenteral formulation precedents, or access to a well-characterized lipid formulation toolbox.
- Other carriers to consider:
- Ethosomes / Transfersomes: softer vesicles for deeper skin penetration.
- SLN/NLC: solid-lipid systems for higher physical stability and distinct release.
- Polymer micelles: great for solubilizing hydrophobic payloads.
For multi-platform programs, see our Module Delivery Systems page to compare options side by side.
Table 1 Comparison of niosomes with liposomes.
| Attribute | Niosomes | Liposomes |
|---|---|---|
| Raw Materials | Non-ionic surfactants + cholesterol | Phospholipids + cholesterol |
| Stability (oxidation/hydrolysis) | Often higher (surfactants are less prone to oxidation) | Variable; natural lipids can oxidize |
| Cost | Generally lower | Often higher |
| Regulatory Familiarity | Good in topical/cosmetic; growing in pharma | Very high in pharma |
| Entrapment Efficiency | Tunable; method-dependent | Tunable; often strong for hydrophilic drugs |
| Typical Use Cases | Topical/dermal, cosmetics, oral | Injectable, topical, oral |
How Niosomes Are Prepared
There are mainly four methods for industrial production of niosomes: thin film hydration, reverse phase evaporation, ether injection, and microfluidics. Each of them offers distinct advantages for pharmaceutical and cosmetic formulations.
Common Preparation Methods
- Thin-Film Hydration (TFH)
Dissolve surfactant + cholesterol in organic solvent → evaporate to thin film → hydrate with aqueous drug → size-reduce (sonication/extrusion).
Fig.2 The thin-film hydration method.2
- Ether/Ethanol Injection
Inject the organic phase into the aqueous phase under stirring. Rapid vesicle formation yields smaller sizes.
- Reverse-Phase Evaporation
Form water-in-oil emulsion → remove solvent → vesicle formation with high aqueous core volume.
Fig.3 The reversed-phase evaporation method.2
- Microfluidic Mixing
Precisely mix solvent and aqueous streams for scalable, reproducible particle sizes and low PDI.
In the industrial-scale production of niosomes, standardized process controls and quality validations are critical for consistent product quality and regulatory compliance.
Industrialization Tips
- Standardize surfactant:cholesterol ratios.
- Control temperature, hydration time, and shear.
- Use in-line filtration and in-line particle sizing proxies.
- Write clear cleaning validation and solvent residual limits.
Performance & Stability: What Actually Moves the Needle
The performance and stability of niosomes are primarily influenced by four key factors, including particle size, zeta potential, surfactant composition, and cholesterol content. These parameters collectively dictate the physical integrity, drug encapsulation efficiency, and shelf life of niosomes. Therefore, understanding and optimizing these parameters are important for the niosome application in both research and industrial settings.
Stability Levers
- Cholesterol % strengthens membranes and limits leakage.
- Surfactant HLB and chain length adjust packing and permeability.
- Zeta potential (±25-35 mV target) helps resist aggregation.
- Cryo/lyo-protectants (e.g., sugars) support freeze-drying.
- Antioxidants / pH buffers reduce degradation.
Release Control
- Decrease vesicle size for faster release; increase for sustained profiles.
- Tune bilayer composition for permeability.
- Adjust lamellarity (multi- vs unilamellar) to manage depot effects.
Key CQAs (Critical Quality Attributes)
- Size & PDI (DLS)
- Zeta potential
- Entrapment Efficiency (EE%) / Drug Loading (DL%)
- In vitro release profile
- Rheology if formulated as gel/cream
Scale-Up and CMC
Scaling niosomes from bench to pilot demands controlled mixing, tight particle specs, and a risk-based CMC package aligned with ICH expectations.
Scale-Up Essentials
- Continuous mixing (e.g., microfluidics) for narrow size and low PDI.
- In-line process analytics to track size trends.
- Sterilization strategy (filtration vs aseptic processing).
- Container-closure compatibility and extractables/leachables screening.
CMC Package (What buyers expect)
- Specifications: size, PDI, zeta, EE%, assay, impurities.
- Release tests: appearance, pH, microbial limits, preservative efficacy (if used).
- Stability: accelerated and long-term (ICH conditions).
- Reports: method validation, residual solvents, and risk controls.
Applications & Case Snapshots (Pharma, Cosmetics, Nutraceuticals)
The application of niosomes spans across pharmaceuticals, cosmetics, and nutraceuticals due to their ability to improve stability, bioavailability, and targeted delivery of diverse bioactive compounds.
Pharmaceuticals
In pharmaceuticals, niosomes serve as effective carriers for both hydrophilic and hydrophobic drugs to enhance therapeutic effects. They are applied for treating diseases, such as cancer, diabetes, and neurological disorders. For instance, compared to free carvedilol, carvedilol delivered by niosomes has demonstrated improved oral bioavailability by protecting the drug from degradation and controlling release profiles. They can encapsulate anticancer drugs, such as doxorubicin, for target specificity and synergistic efficacy against tumors. Recently, niosomes have been extensively explored for protein and peptide drug delivery, including insulin and vaccines, as they can offer protection from degradation and enhance pharmacokinetics upon oral, parenteral, or transdermal administration. In the delivery of plasmid DNA or siRNA, niosomes can be designed to enhance transfection via functionalization.
Cosmetics
In the cosmetic industry, niosomes encapsulate antioxidants, vitamins, and other bioactive cosmetic ingredients by leveraging their bilayer structure. They can improve the penetration, stability, and controlled release of the therapeutic drugs. The adaptability of niosomal compositions allows their application in skin moisturizers, anti-aging creams, and sunscreens. Compared to conventional carriers, they present lower toxicity risks and improved skin compatibility.
Nutraceuticals
Nutraceutical delivery benefits from niosomes' capacity to encapsulate sensitive bioactive natural compounds such as polyphenols, omega fatty acids, and carotenoids. Encapsulation enhances the stability of bioactives against oxidation and environmental degradation while improving absorption upon oral administration.
Want a cross-platform view?
Visit our Module Delivery Systems to match carriers to your route and payload.
How Creative Biolabs Can Help (Service Workflow)
Creative Biolabs provides an end-to-end workflow to plan, build, and validate niosome-based delivery—from surfactant selection and DoE to stability, scale-up, and CMC documentation. Our scientists tailor EE%, size/PDI, and release profiles to your route and payload so you can move from lab concept to manufacturable product with confidence.
Formulation design
Surfactant screening, cholesterol ratio, DoE for EE%/size/PDI.
Prototype build
Lab batches with DLS/PDI/zeta, EE%, and in vitro release.
Route-fit optimization
Niosomal gel/cream/solution; rheology; deposition or PK surrogates.
Stability & scale-up
Process parameters, cleaning validation, and clear batch records.
Characterization & reports
CQA matrix, method transfers, and batch summaries for partners.
Explore adjacent platforms and mix-and-match options on our Module Delivery Systems page.
Related Services You May Be Interested in
FAQs
What are niosomes, and how do they work?
Niosomes are vesicles built from non-ionic surfactants and cholesterol. They encapsulate actives and release them in a controlled way. Therefore, they improve stability, reduce irritation, and support better penetration or bioavailability.
How are niosomes prepared in the lab and on a pilot scale?
Common methods include thin-film hydration, solvent injection, reverse-phase evaporation, and microfluidics. At scale, teams prefer continuous mixing and in-line controls to keep size and PDI consistent.
Niosomes vs liposomes—when should I pick which?
Choose niosomes when you need stable, cost-efficient dermal or oral systems. Choose liposomes when you need phospholipid biomimicry or leverage established parenteral precedents.
What affects entrapment efficiency (EE%) in niosomes?
A niosomal gel suspends niosomes in a gel base for easy application, residence time, and smooth release. It is suitable for topical or transdermal products.
How do you measure and report EE% and DL%?
Separate free drug by centrifugation/dialysis/SEC, quantify with UV/HPLC, and report EE% and DL% using standard equations with method details and recovery checks.
What particle size and PDI are acceptable?
Target 60-200 nm with PDI≤0.2 for uniformity, depending on route and viscosity. However, specifications should link to performance data and stability.
How long is the niosome shelf life, and how is it tested?
Shelf life depends on composition and storage. Teams run accelerated and long-term stability per ICH to confirm size, PDI, zeta, EE%, and assay retention.
Conclusion
Niosomes give teams a stable, cost-effective, and route-flexible way to deliver both hydrophilic and lipophilic actives. Because they enable tunable EE%, controlled release, and gentler dermal performance, they are an excellent first choice for topical, transdermal, and oral projects. Moreover, modern preparation methods such as microfluidic mixing make scale-up and CMC more predictable.
Ready to evaluate niosomes for your payload and route?
Compare platforms on our Module Delivery Systems page.
Or
Talk to our formulation scientists about design-of-experiments, EE% optimization, and scale-up plans tailored to your target product profile.
References
- Bautista-Solano, A. A., Dávila-Ortiz, G., Perea-Flores, M. D. J. & Martínez-Ayala, A. L. A "Comprehensive Review of Niosomes: Composition, Structure, Formation, Characterization, and Applications in Bioactive Molecule Delivery Systems." Molecules 30, 3467 (2025). https://www.mdpi.com/1420-3049/30/17/3467.
- Ge, X., Wei, M., He, S. & Yuan, W.-E. "Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery." Pharmaceutics 11, 55 (2019). https://www.mdpi.com/1999-4923/11/2/55. Distributed under Open Access license CC BY 4.0, without modification.
- Osanloo, M., Assadpour, S., Mehravaran, A., Abastabar, M. & Akhtari, J. "Niosome-loaded antifungal drugs as an effective nanocarrier system: A mini review." CMM https://doi.org/10.18502/cmm.4.4.384 (2019). https://publish.kne-publishing.com/index.php/CMM/article/view/384.
- Fadaei, M. S. et al. "Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds." EXCLI Journal; 23:Doc212; ISSN 1611-2156 https://doi.org/10.17179/EXCLI2023-6868 (2024) doi:10.17179/EXCLI2023-6868. https://www.excli.de/index.php/excli/article/view/6868.
